BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523 AND Prognosis
7 results:

  • 1. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Alternative Splicing: A New Therapeutic Target for ovarian cancer.
    Yao S; Yuan C; Shi Y; Qi Y; Sridha R; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338211067911. PubMed ID: 35343831
    [No Abstract]    [Full Text] [Related]  

  • 3. N6-Methyladenosine-Related RNA Signature Predicting the prognosis of ovarian cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
    Park GB; Chung YH; Kim D
    Oncol Rep; 2017 May; 37(5):3137-3145. PubMed ID: 28350104
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection.
    Rzymski P; Opala T; Wilczak M; Woźniak J; Sajdak S
    Int J Gynaecol Obstet; 2005 Mar; 88(3):292-8. PubMed ID: 15733884
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
    Davidson B; Reich R; Lazarovici P; Ann Flørenes V; Nielsen S; Nesland JM
    Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.